Crohn’s & Colitis News

Stay up-to-date with the most current news and information about the Crohn's & Colitis Foundation, as well as Crohn's disease and ulcerative colitis.

Below you’ll find our most recent press releases, along with other articles written by the foundation. This media content highlights the public research outcomes related to our initiatives, studies, and clinical trials. In addition, you can read our expert commentary related to research articles culled from external media sources. For a complete list of all our news content, please visit the News Archive section.

If you are a member of the media interested in speaking with a Foundation's spokesperson, contact us today.

Most Recent News

Camp Oasis recieved a $5000 from the Allergan Foundation

Orange County Chapter

Thank you to the Allergan Foundation for investing in Camp Oasis with a $5,000 grant! From Left to right: Bill Meury, Allergan Foundation board member and Executive VP, Chief Commercial Officer; Jonathon Kellerman, Allergan Foundation board member and Executive VP, Global Chief Compliance Officer; Denise Desmond, Crohn’s & Colitis Foundation Orange County Chapter, Executive Director, Gwyn Grenrock, Executive Director of The Allergan Foundation; and Alex Kelly, Allergan Foundation President and Executive VP, Chief Communications Officer.

Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Diseases (IBD) Receives Funding

May 17, 2018

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel diseases (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.

Great Day Houston 2018

South Texas Chapter

May 14, 2018

The video of Marni Goldman, pediatric Honored Hero, doing us proud on Great Day Houston!

Crohn’s Disease and Ulcerative Colitis Patient Perspectives on Clinical Trials and Participation

May 7, 2018

Clinical trial recruitment is the biggest barrier to the development and approval of new treatments. In order to understand patient perceptions and improve recruitment, the Crohn’s & Colitis Foundation conducted in-person focus groups over a four-month period in 2016, the results of which are published in the paper "Crohn’s disease and ulcerative colitis patient perspectives on clinical trials and participation."

Leading Patient & Professional Organizations Announce Funding to Improve Communications & Address Shared Decision-making in Inflammatory Bowel Diseases

April 17, 2018

The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.

The Crohn's & Colitis Foundation Selects Diversigen, Inc. as a Preferred Provider for Metagenomics and Microbiome Analysis Services

April 11, 2018

Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.

Can taking accutane lead to ulcerative colitis?

April 6, 2018

exploring the relationship between accutane and ulcerative colitis